[Skip to Content]
[Skip to Content Landing]
Views 200
Citations 0
Invited Commentary
July 12, 2017

Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer

Author Affiliations
  • 1Pancreatic Surgery Unit, Division of Surgery, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden
  • 2Digestive and Liver Disease Unit, Sapienza University of Rome, Rome, Italy
JAMA Surg. Published online July 12, 2017. doi:10.1001/jamasurg.2017.2228

Preoperative chemotherapy and/or chemoradiation is considered today the standard of care for the treatment of locally advanced/borderline resectable pancreatic cancer (PDAC).1

With this regard, terms such as downstaging and neoadjuvant are commonly reported in medical literature and mutually used as synonyms to address preoperative treatment. A first important issue that should be pointed out is a matter of definitions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×